title: Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.
abstract: The use of intravenous nitrogen-containing bisphosphonates (N-BPs) is associated with the appearance of an acute phase response (APR) in a proportion of the patients for reasons that are poorly understood. The APR was attributed to the indirect activation of γδ T cells with the release of interferon-γ and tumor necrosis factor (TNF). Forty patients with postmenopausal or senile osteoporosis (age range = 53-91 years) never previously treated with intravenous (i.v.) bisphosphonate, received a single 5-mg zoledronic acid (ZOL) iv infusion over 15 minutes. White blood cells were counted and analyzed with an automated hematology analyzer (ADVIA 2120i Siemens, New York, USA) and by flow cytometer (BD FACSCanto, Becton Dickinson). The occurrence of APR was defined by the occurrence of fever (>37 °C) during the next 2 days. Forty-two percent of patients (17 of 40) receiving the infusion of ZOL experienced an APR. Compared with the others they were younger (69 ± 7 years versus 74 ± 8 years; p = 0.06), and both the proportion and absolute number of γδ T cells were significant higher (p = 0.02 and p = 0.013, respectively). Nonsignificant differences were found between the two groups for white blood cells and for the other circulating lymphocyte subpopulations. Age was inversely correlated with circulating γδ T cells (p = 0.003) but the difference between the two groups in circulating γδ T cells persisted for age-adjusted values and vice versa. In conclusion, the results of this study indicate that the number of circulating γδ T cells, together with age, are important determinant of the occurrence of APR after intravenous infusion of ZOL and possibly of any other N-BPs.
authors.affiliation: Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Rossini
authors.forename: Silvano
authors.initials: S
authors.lastname: Adami
authors.forename: Ombretta
authors.initials: O
authors.lastname: Viapiana
authors.forename: Riccardo
authors.initials: R
authors.lastname: Ortolani
authors.forename: Antonio
authors.initials: A
authors.lastname: Vella
authors.forename: Elena
authors.initials: E
authors.lastname: Fracassi
authors.forename: Davide
authors.initials: D
authors.lastname: Gatti
mesh_terms: D000210:Acute-Phase Reaction / Q000139:chemically induced* / Q000276:immunology*; D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology*; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects* / Q000494:pharmacology; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000009:adverse effects* / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000276:immunology*; D012307:Risk Factors; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D016692:Receptors, Antigen, T-Cell, gamma-delta; D000077211:Zoledronic Acid